贵圈
政府都对党
- 注册
- 2014-10-21
- 消息
- 32,833
- 荣誉分数
- 6,360
- 声望点数
- 373
Disappointing from Merck. Updated data for efficacy of their Molnupiravir pill in full trial drops down to 30% from 50%, absolute reduction to 3 from 7 per 100 at interim analysis
www.merck.com
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.
新泽西州 KENILWORTH 和迈阿密--(BUSINESS WIRE)--(美国商业资讯)--默克（纽约证券交易所代码：MRK）（在美国和加拿大以外被称为 MSD）和 Ridgeback Biotherapeutics 今天提供了关于莫诺匹韦（MK-4482， EIDD-2801)，一种用于 COVID-19 的研究性口服抗病毒药物。 现在可以从所有注册的参与者 (n=1433) 获得数据。 在该研究人群中，莫奈拉韦将住院或死亡风险从安慰剂组的 9.7% (68/699) 降低至莫奈拉韦组的 6.8% (48/709)，绝对风险降低了 3.0%（95% 置信度） 区间 [CI]：0.1、5.9；名义 p 值 = 0.0218）和 30% 的相对风险降低（相对风险 0.70；95% CI：0.49、0.99）。 安慰剂组报告了 9 例死亡，molnupiravir 组报告了 1 例死亡。 molnupiravir 的不良事件特征与计划的中期分析中报告的特征保持一致。
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19 - Merck.com
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants...
www.merck.com
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine for COVID-19. Data are now available from all enrolled participants (n=1433). In this study population, molnupiravir reduced the risk of hospitalization or death from 9.7% in the placebo group (68/699) to 6.8% (48/709) in the molnupiravir group, for an absolute risk reduction of 3.0% (95% confidence interval [CI]: 0.1, 5.9; nominal p-value=0.0218) and a relative risk reduction of 30% (relative risk 0.70; 95% CI: 0.49, 0.99). Nine deaths were reported in the placebo group, and one in the molnupiravir group. The adverse event profile for molnupiravir remained consistent with the profile reported at the planned interim analysis.
新泽西州 KENILWORTH 和迈阿密--(BUSINESS WIRE)--(美国商业资讯)--默克（纽约证券交易所代码：MRK）（在美国和加拿大以外被称为 MSD）和 Ridgeback Biotherapeutics 今天提供了关于莫诺匹韦（MK-4482， EIDD-2801)，一种用于 COVID-19 的研究性口服抗病毒药物。 现在可以从所有注册的参与者 (n=1433) 获得数据。 在该研究人群中，莫奈拉韦将住院或死亡风险从安慰剂组的 9.7% (68/699) 降低至莫奈拉韦组的 6.8% (48/709)，绝对风险降低了 3.0%（95% 置信度） 区间 [CI]：0.1、5.9；名义 p 值 = 0.0218）和 30% 的相对风险降低（相对风险 0.70；95% CI：0.49、0.99）。 安慰剂组报告了 9 例死亡，molnupiravir 组报告了 1 例死亡。 molnupiravir 的不良事件特征与计划的中期分析中报告的特征保持一致。
